Fresenius Medical Care Sees U.S. Plans for Kidney Disease as Positive
Browser Upgrade Recommended: Our website has detected that you are using a version of Internet Explorer that will prevent you from accessing certain features on FMCNA.com. We strongly recommend that you use a different browser to optimize your viewing experience. Supported browsers include Chrome, Edge, Firefox, and Safari.
We are actively monitoring the novel coronavirus (COVID-19) pandemic. Learn About the steps that we are taking to protect our patients, employees, physicians, and partners. If you are a patient with questions or concerns, please find additional information at FreseniusKidneyCare.com and AzuraVascularCare.com
National Cardiovascular Partners (NCP), a division of Fresenius Medical Care North America (FMCNA), is the market leader of the outpatient, hybrid cardiovascular center (ASC/office-based lab) model. Partnering with physician entrepreneurs, NCP oversees the development, management, and operations of the centers, allowing physicians to focus on providing exceptional and innovative patient care.
We are pleased to announce that Medicare patients are now approved to receive certain cardiac treatments in the outpatient setting in addition to diagnostics. By allowing for diagnosis and treatment in one location, patients will no longer have to travel to multiple appointments. The newly approved treatments under Medicare relate to three specific percutaneous coronary intervention (PCI) procedures, including drug eluding stent placement.
To learn more, please read the official fact sheet from the Centers for Medicare and Medicaid Services website.